Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 20 03 2019
accepted: 17 06 2019
entrez: 25 7 2019
pubmed: 25 7 2019
medline: 21 10 2020
Statut: epublish

Résumé

The trimeric envelope spikes on the HIV-1 virus surface initiate infection and comprise key targets for antiviral humoral responses. Circulating virions variably present intact envelope spikes, which react with neutralizing antibodies; and altered envelope structures, which bind non-neutralizing antibodies. Once bound, either type of antibody can enable humoral effector mechanisms with the potential to control HIV-1 infection

Identifiants

pubmed: 31338095
doi: 10.3389/fimmu.2019.01512
pmc: PMC6628914
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Epitopes 0
HIV Antibodies 0
HIV Envelope Protein gp120 0
HIV Envelope Protein gp41 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1512

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI120756
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI124912
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM117836
Pays : United States

Références

J Virol. 2001 Mar;75(6):2993-3000
pubmed: 11222724
Biochemistry. 2002 Jan 22;41(3):697-705
pubmed: 11790090
Nature. 2002 Oct 17;419(6908):743-7
pubmed: 12384704
AIDS. 2002 Dec 6;16(18):2409-17
pubmed: 12461414
J Virol. 2003 Jan;77(1):353-65
pubmed: 12477840
J Virol. 2003 Jan;77(2):1084-91
pubmed: 12502824
Nature. 2003 Mar 20;422(6929):307-12
pubmed: 12646921
J Virol. 2003 May;77(10):5678-84
pubmed: 12719560
Science. 2003 Jun 27;300(5628):2065-71
pubmed: 12829775
Protein Sci. 1992 May;1(5):563-74
pubmed: 1304355
J Virol. 1992 Feb;66(2):848-56
pubmed: 1370558
J Med Primatol. 1992 Feb-May;21(2-3):50-8
pubmed: 1433267
AIDS Res Hum Retroviruses. 2005 Feb;21(2):171-89
pubmed: 15725757
Virology. 2005 Jul 20;338(1):154-72
pubmed: 15932765
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13372-7
pubmed: 16174734
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8
pubmed: 16219699
J Virol. 2006 Feb;80(3):1414-26
pubmed: 16415019
Nat Methods. 2006 Feb;3(2):83-9
pubmed: 16432516
J Virol. 2006 Mar;80(5):2515-28
pubmed: 16474158
FASEB J. 2006 Sep;20(11):1762-74
pubmed: 16940148
J Virol. 2006 Dec;80(23):11776-90
pubmed: 16971434
J Immunol. 1990 Nov 15;145(10):3276-82
pubmed: 1700004
J Virol. 1991 Sep;65(9):4832-8
pubmed: 1714520
Curr HIV Res. 2007 Nov;5(6):561-71
pubmed: 18045112
Nature. 1991 Oct 3;353(6343):393
pubmed: 1815549
Nature. 2008 Sep 4;455(7209):109-13
pubmed: 18668044
PLoS Pathog. 2009 May;5(5):e1000433
pubmed: 19436712
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Lancet. 1990 Dec 22-29;336(8730):1538-41
pubmed: 1979369
Virology. 2010 Mar 15;398(2):224-32
pubmed: 20060554
J Virol. 2010 Apr;84(7):3382-95
pubmed: 20089658
PLoS Pathog. 2010 May 13;6(5):e1000890
pubmed: 20485520
Clin Vaccine Immunol. 2010 Aug;17(8):1244-51
pubmed: 20534793
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
J Biol Chem. 2011 May 27;286(21):18878-89
pubmed: 21454482
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6
pubmed: 21690411
Nature. 2011 Nov 23;480(7377):336-43
pubmed: 22113616
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
pubmed: 23100539
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20419-24
pubmed: 23185020
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78
pubmed: 23237851
J Biol Chem. 1990 Jun 25;265(18):10373-82
pubmed: 2355006
J Virol. 2014 Feb;88(3):1795-808
pubmed: 24284318
Science. 1986 Dec 12;234(4782):1392-5
pubmed: 2431482
Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202
pubmed: 2452447
PLoS One. 2014 Feb 14;9(2):e88735
pubmed: 24551145
J Virol. 2014 May;88(9):5165-70
pubmed: 24554654
J Immunol. 2014 Sep 15;193(6):3113-25
pubmed: 25135832
J Immunol. 2014 Sep 15;193(6):3126-33
pubmed: 25143442
Vaccine. 2015 Jan 3;33(2):388-95
pubmed: 25444812
PLoS Pathog. 2015 Mar 25;11(3):e1004772
pubmed: 25807494
J Virol. 2015 Sep;89(17):8840-54
pubmed: 26085162
PLoS Pathog. 2015 Aug 03;11(8):e1005042
pubmed: 26237403
Retrovirology. 2015 Sep 24;12:81
pubmed: 26399966
Science. 2016 Mar 4;351(6277):1043-8
pubmed: 26941313
Sci Rep. 2016 Nov 09;6:36685
pubmed: 27827447
Sci Rep. 2017 Apr 19;7(1):948
pubmed: 28424455
Elife. 2017 May 26;6:
pubmed: 28548638
Cell. 2017 Aug 10;170(4):637-648.e10
pubmed: 28757252
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9893-E9902
pubmed: 29087304
Cell. 2018 Jun 14;173(7):1783-1795.e14
pubmed: 29731169
Proc Natl Acad Sci U S A. 1985 Jul;82(14):4813-7
pubmed: 2991896
Vaccines (Basel). 2018 Jun 29;6(3):null
pubmed: 29966222
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5
pubmed: 30092199
Cell. 2018 Aug 9;174(4):938-952.e13
pubmed: 30096313
Nat Immunol. 2018 Nov;19(11):1179-1188
pubmed: 30333615
Nat Immunol. 2018 Nov;19(11):1169-1178
pubmed: 30333617
Immunity. 2019 Jan 15;50(1):241-252.e6
pubmed: 30552025
J Virol. 2019 Mar 5;93(6):
pubmed: 30626682
Nature. 1988 Aug 4;334(6181):440-4
pubmed: 3405290
Science. 1994 Nov 11;266(5187):1024-7
pubmed: 7973652
Curr Opin Immunol. 1996 Aug;8(4):540-5
pubmed: 8794008
Biophys J. 1997 Apr;72(4):1878-86
pubmed: 9083691
J Virol. 1998 Jun;72(6):4694-703
pubmed: 9573233
Nature. 1998 Jun 18;393(6686):648-59
pubmed: 9641677
Nature. 1998 Jun 18;393(6686):705-11
pubmed: 9641684
J Virol. 1998 Oct;72(10):7992-8001
pubmed: 9733838
AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1271-80
pubmed: 9764911

Auteurs

Krishanu Ray (K)

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States.

Meron Mengistu (M)

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.

Chiara Orlandi (C)

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.

Marzena Pazgier (M)

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States.

George K Lewis (GK)

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States.

Anthony L DeVico (AL)

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH